NL300067I1 - Gemodificeerde antilichamen. - Google Patents

Gemodificeerde antilichamen.

Info

Publication number
NL300067I1
NL300067I1 NL300067C NL300067C NL300067I1 NL 300067 I1 NL300067 I1 NL 300067I1 NL 300067 C NL300067 C NL 300067C NL 300067 C NL300067 C NL 300067C NL 300067 I1 NL300067 I1 NL 300067I1
Authority
NL
Netherlands
Prior art keywords
modified antibodies
framework regions
origin
antibody
identified
Prior art date
Application number
NL300067C
Other languages
English (en)
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803228A external-priority patent/GB8803228D0/en
Priority claimed from GB888804464A external-priority patent/GB8804464D0/en
Application filed by British Tech Group filed Critical British Tech Group
Publication of NL300067I1 publication Critical patent/NL300067I1/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NL300067C 1988-02-12 2001-10-10 Gemodificeerde antilichamen. NL300067I1 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888803228A GB8803228D0 (en) 1988-02-12 1988-02-12 Improvements in/relating to antibodies
GB888804464A GB8804464D0 (en) 1988-02-25 1988-02-25 Improvements in/relating to antibodies

Publications (1)

Publication Number Publication Date
NL300067I1 true NL300067I1 (nl) 2001-12-01

Family

ID=26293475

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300067C NL300067I1 (nl) 1988-02-12 2001-10-10 Gemodificeerde antilichamen.

Country Status (13)

Country Link
EP (1) EP0328404B1 (nl)
JP (2) JP3121823B2 (nl)
AT (1) ATE95068T1 (nl)
AU (1) AU618989B2 (nl)
CA (1) CA1339198C (nl)
DE (2) DE68909441T2 (nl)
DK (1) DK174854B1 (nl)
ES (1) ES2059719T3 (nl)
GB (1) GB2216126B (nl)
LU (1) LU90842I2 (nl)
NL (1) NL300067I1 (nl)
NZ (1) NZ227968A (nl)
WO (1) WO1989007452A1 (nl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69024814T2 (de) * 1989-09-19 1996-07-18 Centocor Inc Verfahren zur verbesserten herstellung von menschlichen antikörpern sowie hierzu benutzte zellen
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
EP1362868A3 (en) * 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AU671807B2 (en) * 1991-10-15 1996-09-12 Btg International Limited CDw52 - specific antibody for treatment of T-cell mediated inflammation of the joints
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
CA2150344C (en) * 1992-11-28 2001-02-13 Kiyoto Nishiyama Method for producing exogenous protein
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
JP4503706B2 (ja) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
EP1419236A4 (en) 2001-07-24 2005-08-03 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
WO2004087210A1 (ja) * 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha 抗cd52抗体による調節性t細胞分化誘導･増殖方法およびそのための医薬組成物
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
KR20160103160A (ko) 2009-05-13 2016-08-31 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
AU2018240938A1 (en) 2017-03-24 2019-10-10 Zenyaku Kogyo Co., Ltd. Anti-IgM/B cell surface antigen bispecific antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product

Also Published As

Publication number Publication date
DK174854B1 (da) 2003-12-22
JPH02503514A (ja) 1990-10-25
NZ227968A (en) 1992-01-29
JPH11228600A (ja) 1999-08-24
AU618989B2 (en) 1992-01-16
ES2059719T3 (es) 1994-11-16
LU90842I2 (fr) 2001-11-26
JP3121823B2 (ja) 2001-01-09
ATE95068T1 (de) 1993-10-15
EP0328404B1 (en) 1993-09-29
AU3062689A (en) 1989-09-06
WO1989007452A1 (en) 1989-08-24
DK502189D0 (da) 1989-10-10
DE10199051I1 (de) 2002-01-10
DK502189A (da) 1989-10-12
GB2216126B (en) 1992-06-03
DE10199051I2 (de) 2005-05-04
EP0328404A1 (en) 1989-08-16
DE68909441T2 (de) 1994-02-10
DE68909441D1 (de) 1993-11-04
CA1339198C (en) 1997-08-05
GB8902978D0 (en) 1989-03-30
GB2216126A (en) 1989-10-04

Similar Documents

Publication Publication Date Title
DE68909441T2 (de) Modifizierte Antikörper.
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
ES2097808T3 (es) Anticuerpos de marco conservado mutado y su preparacion.
ES2137354T3 (es) Moleculas de anticuerpo anti-vla4 recombinante.
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69029015T2 (de) Antikörper gegen menschlichen Interleukin-6-Rezeptor
FI903464A0 (fi) Foerfarande foer oxiderande denaturering av proteinanalyter.
DE3788148T2 (de) Monoklonale Antikörper und deren Verwendung.
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
ID25978A (id) Antibodi anti-fas
DE3579573D1 (de) Logisches gatter mit "verdrahteter" und-funktion-eingangsstufe unter verwendung von feldeffekttransistoren.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
DE69111429T2 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
ATE263784T1 (de) Anti-megakaryozyten monoklonaler antikörper 97a6
ATE148163T1 (de) Monoklonale antikörper gegen leptosphaeria
ATE136937T1 (de) Antikörper gegen hamsterimmunglobulinen
ATE148162T1 (de) Monoklonale antikörper gegen mycosphaerella-arten
DE69026453T2 (de) Antirhodopsiner monoklonaler Antikörper and seine Verwendung
ATE99333T1 (de) Immunogen und seine verwendung zur gewinnung von antikoerpern gegen haemoglobin a1c.